Tin tức & Cập nhật
Xem bài viết Tim mạch
Xem
Chỉ hiển thị Multimedia

Aficamten retains upper hand over metoprolol for oHCM in subanalysis
14 Sep 2026
bởiAudrey Abella
Results from a subanalysis of the MAPLE-HCM* trial presented at ESC 2026 continue to support the superiority of aficamten over metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) irrespective of beta-blocker (BB) use at screening and prior standard-of-care (SoC) status.
Aficamten retains upper hand over metoprolol for oHCM in subanalysis
14 Sep 2026
Uromodulin levels do not predict hypertension
11 Sep 2026
bởiStephen Padilla
Uromodulin, as a protein and genetic biomarker, is not a reliable predictor of hypertension or hypertension-related outcomes, reveals a study. However, it may have potential use in the prediction of other cardiovascular outcomes.
Uromodulin levels do not predict hypertension
11 Sep 2026
Inclisiran outdoes BPA for LDL-C lowering in high CV risk patients
11 Sep 2026
bởiAudrey Abella
In the phase IV VICTORION-Challenge trial, inclisiran outperforms bempedoic acid (BPA) for lowering LDL-C in individuals with high and very high cardiovascular (CV) risk.






